Zobrazeno 1 - 10
of 593
pro vyhledávání: '"Tsuneharu MIKI"'
Autor:
Kazuya Mikami, Kotaro Ozasa, Tsuneharu Miki, Yoshiyuki Watanabe, Mitsuru Mori, Tatsuhiko Kubo, Koji Suzuki, Kenji Wakai, Masahiro Nakao, Akiko Tamakoshi, for the JACC Study Group
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 7298-7307 (2021)
Abstract Dairy products have been indicated as a risk factor for prostate cancer. However, only a few epidemiological studies have reported dairy products as being a risk factor for prostate cancer in Japan, reporting contradictory results. We theref
Externí odkaz:
https://doaj.org/article/44cf1b29a93a48c48350850a9c0481ba
Autor:
Yasuhiro Yamada, Koji Okihara, Tsuyoshi Iwata, Koji Masui, Kazumi Kamoi, Kei Yamada, Tsuneharu Miki
Publikováno v:
Asian Journal of Andrology, Vol 17, Iss 6, Pp 899-903 (2015)
External beam radiotherapy (EBRT) is a standard treatment for prostate cancer. Despite the development of novel radiotherapy techniques such as intensity-modulated conformal radiotherapy, the risk of local recurrence after EBRT has not been obviated.
Externí odkaz:
https://doaj.org/article/816604ec874948f4bde6400e8ab8a3b2
Autor:
Siew-Kee Low, Koya Fukunaga, Atsushi Takahashi, Koichi Matsuda, Fumiya Hongo, Hiroyuki Nakanishi, Hiroshi Kitamura, Takamitsu Inoue, Yoichiro Kato, Yoshihiko Tomita, Satoshi Fukasawa, Tomoaki Tanaka, Kazuo Nishimura, Hirotsugu Uemura, Isao Hara, Masato Fujisawa, Hideyasu Matsuyama, Katsuyoshi Hashine, Katsunori Tatsugami, Hideki Enokida, Michiaki Kubo, Tsuneharu Miki, Taisei Mushiroda
Publikováno v:
PLoS ONE, Vol 11, Iss 2, p e0148177 (2016)
Sunitinib is a tyrosine kinase inhibitor and used as the first-line treatment for advanced renal cell carcinoma (RCC). Nevertheless, inter-individual variability of drug's toxicity was often observed among patients who received sunitinib treatment. T
Externí odkaz:
https://doaj.org/article/a276813a941f4f4aa59c01e5e9edcb45
Autor:
Masakatsu Oishi, Yosuke Iizumi, Tomoyuki Taniguchi, Wakana Goi, Tsuneharu Miki, Toshiyuki Sakai
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e55922 (2013)
Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapeutic agent. Recombinant human Apo2L/TRAIL has been under clinical trials, whereas various kinds of malignant tumors have resistance to Ap
Externí odkaz:
https://doaj.org/article/c8968cb76c134178b18d36c1d69487bf
Autor:
John W Davis, Tsuneharu Miki, Atif Akdas, Hiroki Watanabe, Ziya Kirkali, Run Wang, R Joseph Babaian
Publikováno v:
Asian Journal of Andrology, Vol 17, Iss 6, Pp 863-863 (2015)
Externí odkaz:
https://doaj.org/article/55be662fe6ac489bb78ba0fc41cd4030
Autor:
Toshiyuki Sakai, Osamu Ukimura, Tsuneharu Miki, Yukako Morioka, Toshiya Takamura, Yuichi Aono, Tomoyuki Taniguchi, Shusuke Yasuda, Mano Horinaka, Seijiro Toriyama
T24 or UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 48 h in T24 cells or 72 h in UM-UC-11 cells. A. Quantitative real-time RT-PCR of DR5 mRNA. The internal control was β2MG. Values show fold change in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c51d693740aed67b2197e0754ec99f2
https://doi.org/10.1158/1535-7163.22504234
https://doi.org/10.1158/1535-7163.22504234
Autor:
Toshiyuki Sakai, Osamu Ukimura, Tsuneharu Miki, Yukako Morioka, Toshiya Takamura, Yuichi Aono, Tomoyuki Taniguchi, Shusuke Yasuda, Mano Horinaka, Seijiro Toriyama
A. T24 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 24 h. Cell lysates were subjected to immunoprecipitation with anti-DR5 antibody or an isotype control. Input cell lysates and anti-DR5 immunoprecipitates were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f6c21e375ce4dc3e0fbae690d27ebff
https://doi.org/10.1158/1535-7163.22504228
https://doi.org/10.1158/1535-7163.22504228
Autor:
Toshiyuki Sakai, Osamu Ukimura, Tsuneharu Miki, Yukako Morioka, Toshiya Takamura, Yuichi Aono, Tomoyuki Taniguchi, Shusuke Yasuda, Mano Horinaka, Seijiro Toriyama
A. UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 72 h. Quantitative real-time RT-PCR of TRAIL mRNA was performed. The internal control was β2MG. Values show fold change in TRAIL mRNA expression compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c033076cddf6f19b161454aef2176a3
https://doi.org/10.1158/1535-7163.22504231
https://doi.org/10.1158/1535-7163.22504231
Autor:
Toshiyuki Sakai, Osamu Ukimura, Tsuneharu Miki, Yukako Morioka, Toshiya Takamura, Yuichi Aono, Tomoyuki Taniguchi, Shusuke Yasuda, Mano Horinaka, Seijiro Toriyama
T24 or UM-UC-11 cells were treated with the indicated concentrations of OBP-801 and/or celecoxib for 48 h in T24 cells or 72 h in UM-UC-11 cells. Quantitative real-time RT-PCR of FLIP (A) and survivin (B) mRNA were performed. The internal control was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::116ddddbc9626d5616878798d353d527
https://doi.org/10.1158/1535-7163.22504237
https://doi.org/10.1158/1535-7163.22504237
Autor:
Junko Murai, Yves Pommier, Shunichi Takeda, Tsuneharu Miki, Terukazu Nakamura, Toshiaki Kogame, Toru Fukushima, Hiroyasu Shimizu, Yuko Maede
PDF - 7482KB, Supplementary Table 1. DT40 isogenic mutant cell lines used in this study. Cell lines are ordered as in Figure 1. Supplementary Figure 1. Generation of the ATG5-deficient DT40 cells. Supplementary Figure 2. Linearity between cells per w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1f7100595cc9f5c8b926ecfd8f20e86
https://doi.org/10.1158/1535-7163.22503661
https://doi.org/10.1158/1535-7163.22503661